A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

January 29, 2025

Study Completion Date

January 29, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

[ 14C]-labeled RO7269162

Participants will receive one oral dose of \[14C\]-labeled RO7269162.

Trial Locations (1)

ICON Health sciences research center, Groningen

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT06733298 - A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants | Biotech Hunter | Biotech Hunter